



Research on LLM in medicine



Prof. Xudong Lu

College of Biomedical Engineering & Instrumentation
Zhejiang University, China




LLM is changing the world

Trends of Publications Related to LLM on Arxiv (Until June 27th)



8 billion parameters



LLM has gained attention from both academia and industry



LLM is changing the world

nature medicine

Explore content ▾ About the journal ▾ Publish with us ▾

[nature](#) > [nature medicine](#) > [review articles](#) > [article](#)

Review Article | Published: 17 July 2023

Large language models in medicine

Arun James Thirunavukarasu, Darren Shu Jeng Ting, Kabilan Elangovan, Laura Gutierrez, Ting Fang Tan
& Daniel Shu Wei Ting

[Nature Medicine](#) 29, 1930–1940 (2023) | [Cite this article](#)

44k Accesses | 320 Citations | 103 Altmetric | [Metrics](#)

THE LANCET

Access provided by Zhejiang University Library

This journal Journals Publish Clinical Global health Multimedia Events About


CORRESPONDENCE | VOLUME 401, ISSUE 10377, P641, FEBRUARY 25, 2023

Download Full Issue

The promise of large language models in health care

Anmol Arora • Ananya Arora

Published: February 25, 2023 • DOI: [https://doi.org/10.1016/S0140-6736\(23\)00216-7](https://doi.org/10.1016/S0140-6736(23)00216-7)



Med-PaLM M (Google)


The medical field is one of the key research focuses of LLM



Our research on LLM-medicine



浙江大學
1897
ZHEJIANG UNIVERSITY




Methodology to optimize LLM and empower medical devices/systems with clinical data and knowledge




Our research on LLM-medicine



浙江大学
ZHEJIANG UNIVERSITY



Prompt Engineering




Parameter Efficient Fine-Tuning



Retrieval Augmented Generation

LLM Optimization Methods



Breast Cancer Out-of-hospital Management Agent
—**Breast-COMA**

Tumor Board (Precision Oncology Decision Support)
—**Patient Data Extraction & Applications**




1



Breast Cancer Out-of-hospital Management Agent Breast-COMA



Background of Breast-COMA



The incidence and mortality of breast cancer are the first among females globally.



Adverse events and accompanying diseases threaten breast cancer patients' health out of hospital.




Target of Breast-COMA

Traditional APP's Disadvantage



- Steep learning curve
- Templated Interaction
- Manual support requirements





Breast-COMA: Follow-up S-Agent



How to monitor the patient's quality of life and occurrence of adverse events?



Self-reported by the patients

Patient Reported Outcome (PRO) :

Directly from the patient, any reports on the patient's health status, without interpretation by a clinician or other individuals.

15:14 录入表单数据

术后反馈问卷

*在术前您是否感受到疼痛不适?

没有
 轻度
 中度
 严重
 非常严重

*在术前您是否感受到害怕或者焦虑不安?

没有
 轻度
 中度
 严重
 非常严重

*请您回忆在手术过程中，您是否感受到疼痛不适?


没有
 轻度

提交表单

- Survey Fatigue
- Low interactivity



Low Response Rate



Chat-ePRO




Breast-COMA: Follow-up S-Agent

□ Chat-ePRO

Utilize **Prompt Engineering** and **Knowledge**

Challenges

- How to instruct LLM to **actively collect target PRO forms?**
- How to **maintain context consistency** when dialogues are too long?
- How to **extract structured PRO data** from the dialogues economically in real time?






Breast Cancer Out-of-hospital Management Agent — Breast-COMA

□ Follow-up S-Agent: Chat-ePRO —— Method

Challenge: How to extract structured PRO data from the dialogues economically in real time? Why not LLM?

LLM's criteria are **difficult to align with the human** and are **unstable**. Furthermore, LLM will increase the system **time and economic cost**.





Breast-COMA: Follow-up S-Agent


□ Chat-ePRO: Pilot Study Design

Inclusion Criteria:

Patients who received surgical treatment at Sir Run Run Shaw Hospital, and were diagnosed with breast cancer or other benign breast tumors, had undergone surgical procedures, and were willing to participate in regular follow-up.

Exclusion Criteria:

Patients with malignant tumors in other parts of the body.



15:14 5G

录入表单数据

术后反馈问卷

*在术前您是否感受到疼痛不适?

没有
 轻度
 中度
 严重
 非常严重

Did you experience any pain or discomfort before the surgery?

- None
- Mild
- Moderate
- Severe
- Very severe

*在术前您是否感受到害怕或者焦虑不安?

没有
 轻度
 中度
 严重
 非常严重

Did you feel afraid or anxious before the surgery?

- None
- Mild
- Moderate
- Severe
- Very severe

*请您回忆在手术过程中，您是否感受到疼痛不适?


没有
 轻度

Did you experience any pain or discomfort during the surgical procedure?

- None
- Mild

提交表单

Submit Form



(c) Electronic Form-based ePRO

(d) Rule-based Chatbot ePRO

(e) Chat-ePRO



Breast-COMA: Follow-up S-Agent

□ Chat-ePRO: Performance of Algorithm extracting structured data from dialogue

- Dialogue Generation Ability: **Low error rate** (Average: 4.3%)

Form Name	n_{Item}	n_{raw}	n_C	Error Rate
Fact-B	36	2160	2064	4.4%
BIBCQ	44	1144	1101	3.8%
TMI	12	840	800	4.8%

- Data Extraction Ability: **Improvement of F1** (F1: 0.78 → 0.96) , **Decline of inference time** (8.2s → 1.2s) .


Task	Fact-B			BIBCQ			TMI		
	P	R	F1	P	R	F1	P	R	F1
Classification	0.90	0.88	0.88	0.81	0.83	0.81	0.83	0.80	0.78
Semantic Matching	0.90	0.87	0.88	0.79	0.76	0.74	0.85	0.84	0.84
Contrastive Learning	0.93	0.90	0.91	0.92	0.91	0.90	0.96	0.95	0.96
Zero-shot (ChatGPT)	0.57	0.54	0.54	0.66	0.62	0.57	0.73	0.74	0.73
Few-shot (ChatGPT)	0.77	0.70	0.67	0.75	0.81	0.75	0.80	0.83	0.78



Breast Cancer Out-of-hospital Management Agent — Breast-COMA

□ Follow-up S-Agent: Chat-ePRO —— Result

Pilot Study Result:



Chat-ePRO significantly improved the response rate



Ok, I've recorded your answer. The next question is, "Because I am not in good health, I cannot meet the needs of my family." Do you think that description matches your feelings? The options are: 0: Not at all; 1: a little bit; 2: some; 3: equivalent; 4: Very much



Can you define what is the needs of my family?



"Family needs" refer to household activities in daily life, such as cooking, washing, etc., or caring for family members, such as spending time with children, caring for the elderly, etc. This question wants to know if your physical condition is affecting your ability to complete these family activities. Please choose the best answer according to your situation in the past 7 days.



Not at all


Chat-ePRO could respond to queries and guide patients to finish PRO forms.




Breast Cancer Out-of-hospital Management Agent — Breast-COMA

□ Follow-up S-Agent: Chat-ePRO —— Result


Pilot Study Result:



(a) Variance of Evaluation Scores



(b) Subjective Evaluation Result



(c) Evaluation Scores of QA Pairs

After removing the divergence ($\text{var} > 2$) :

- 8% of doctors held negative attitude to Chat-ePRO
 - 78% of doctors held positive attitude to Chat-ePRO




Breast-COMA: Diagnosis S-Agent (In progress)


□ Diagnosis S-Agent: RP-LLM—— Introduction (In Progress)

RP-LLM: Breast Cancer Risk Prediction Large Language Model Enhanced by Machine Learning Models

➤ Poor clinical accessibility of prediction models




➤ Difficult for large language model to predict stably





Breast Cancer Out-of-hospital Management Agent — Breast-COMA

□ Diagnosis S-Agent: RP-LLM—— Method (In Progress)



Evaluation Matrix:



- Risk Prediction Accuracy
- Data Collection Accuracy
- User Preference
- Expert Evaluation



Breast-COMA: Intervention S-Agent (In progress)

□ Intervention S-Agent: MM-BRAG —— Introduction (In Progress)

MM-BRAG: Optimizing Multi-modal Large Language Models for Breast Cancer via Retrieval Augmented Generation




Complexity of Medical Knowledge: Multi-modal, Multi-resources



Breast Cancer Out-of-hospital Management Agent — Breast-COMA

□ Intervention S-Agent: MM-BRAG —— Related Work (In Progress)


Medical LLM with RAG



Almanac (Stanford, 2024)

Knowledge base is limited to text format

Retrieval-Augmented Visual QA




FLMR (University of Cambridge, 2024)

Retrieved images are limited to patches of original image



Breast Cancer Out-of-hospital Management Agent —— Breast-COMA

□ Intervention S-Agent: MM-BRAG —— Method (In Progress)







Breast Cancer Out-of-hospital Management Agent —— Breast-COMA

□ Intervention S-Agent: MM-BRAG —— Result (In Progress)

- Step1: Collecting breast cancer multi-modal knowledge base



- Step2: Collecting breast cancer model evaluation dataset



- Step3: Training and evaluating MM-BRAG (In Progress)



Discussions of Breast-COMA

- **Privacy issue:**

Using the ChatGPT API resulted in **patients' data being public**, violating patients' privacy rights.

- **Security issue:**

LLM **lacks professionalism and interpretability**, posing potential security risks to patients.

- **Prompt engineering limitations:**

Prompt design **lacks clear optimization directions** and relies on human experience.

Few-shot is extremely sensitive to example selection, distribution, and design.

It is difficult for LLM to **balance accuracy and cost**.




2

Tumor Board

Patient Data Extraction & Applications




□ MDT is a core component of precision medicine




- MDT decision making and evaluation throughout the patient's treatment
- Many-to-one, patient-centered treatment

► Key to MDT: integration of patient information

- Patients with **long duration**: requiring a concise and comprehensive summary



Proportion of patients with a disease duration of more than 6 months (40/63)
23.06-23.11, BZ, Breast MDT




Proportion of patients with a disease duration of more than 6 months (40/63)
23.05-23.11, BZ, Gastroenterology MDT

- Participants with **various background**: requiring a quick common consensus

► Patient Timeline could support MDT

"its use replaces the **time-consuming and frustrating** process of searching for various key information within distributed reports"



Feedback before and after application of Patient Timeline (Centre Léon Bérard & ROCHE)

the level of satisfaction (6.8->8)
the confidence in decision-making (5.6->8)





□ OptimalMEE: Optimizing LLMs for MEE

Task Description

Extract multiple events of different event types from clinical notes

Patient presented in November 2021 following a chest CT finding a mass in the lower lobe of the left lung during a routine physical examination. A full-body PET-CT on November 23, 2021, revealed a tumor near the hilum of the lower lobe of the left lung, approximately 3.8×3.4cm, adherent to the pleura. Additional small nodules were scattered throughout both lungs, and the left hilar and mediastinal lymph nodes in zone 7 showed increased radiotracer uptake. A biopsy was performed, revealing adenocarcinoma of the lung with an EGFR exon 21 mutation. The patient was treated with oral Tarceva for two months, resulting in a reduction of the tumor size upon follow-up CT. On February 14, 2022, a left lower lobectomy was performed in our hospital's thoracic surgery department. Postoperative pathology indicated invasive adenocarcinoma, poorly differentiated, with a tumor size of 3.1×2.1×2.1cm. Residual cancer was present (RVT%≈0%, MRD not achieved), with pleural invasion, no aeroduct spread, vascular tumor thrombi, and nerve invasion. Lymph node metastasis was found in the 7s group (1/1), with no other metastases seen. The tumor was staged as ypT2aN2a. Postoperative treatment continued with oral Osimertinib, followed by adjuvant radiotherapy on April 14, 2022, delivering 50Gy in 25 fractions to 95% PTV (left bronchial stump + mediastinal lymph nodes 7, 10L, drainage area). A PET-CT on January 28, 2023, showed postoperative and post-treatment changes in the left lung cancer compared to the November 22, 2021, PET-CT: 1) No high metabolism at the bronchial stump. New multiple patchy, blurry shadows in both lungs, some with increased metabolism, suggestive of inflammation. 2) New lymph node metastasis in the left axilla. 3) New multiple metastases: left pleural metastasis, left pleural effusion, subcutaneous nodules in the left chest wall, and bone metastasis in the T5 vertebra. 4) Left adrenal nodule size unchanged with slightly increased metabolism, suspicious for metastasis, to be confirmed with enhanced imaging. An axillary lymph node biopsy on January 31, 2023, revealed poorly differentiated cancer infiltration in fibrous connective tissue, likely lung cancer metastasis given the history. PD-L1 (22C3) TPS was 3%, and tissue gene testing indicated an EGFR exon 21 mutation, while blood gene testing showed no mutation. Chemotherapy with Pemetrexed + Carboplatin + Bevacizumab + Atezolizumab was initiated on February 28, 2023, and March 21, 2023, for cycles 1 and 2, respectively. The treatment was associated with gastrointestinal reactions, slight blood pressure fluctuations, and grade III neutropenia. A follow-up enhanced chest CT after cycle 2 showed reduced pleural effusion and slightly smaller lymph nodes in the left axilla, with a non-CR, non-PD evaluation. Chemotherapy with Pemetrexed + Carboplatin + Bevacizumab + Atezolizumab was continued for cycles 3 and 4 on April 11, 2023, and May 4, 2023, respectively. A subsequent enhanced chest CT on May 15, 2023, indicated an increase in soft tissue density near the left hilum and left pulmonary artery, suggesting possible recurrence and progression of disease (PD). Subsequent cycles of Bevacizumab + Atezolizumab were administered on May 25, 2023, June 15, 2023, July 6, 2023, and July 27, 2023. An thyroid function test on August 15, 2023, indicated hypothyroidism.






□ OptimalMEE: Optimizing LLMs for MEE

Traditional Methods


a. Rule-based Methods

- Dictionary, Template, Dependency Tree, ...



b. Deep Learning-based Methods

- Subtasks: NER, RE, Classification, ...



Challenges

Event Elements Scattering

21 mutation, while blood gene testing showed no mutation. Chemotherapy with Pemetrexed + Carboplatin + Bevacizumab + Atezolizumab was initiated on February 28, 2023, and March 21, 2023, for cycles 1 and 2, respectively. The treatment was associated with gastrointestinal reactions, slight blood pressure fluctuations, and grade III neutropenia. A follow-up enhanced chest CT after cycle 2 showed reduced pleural effusion and slightly smaller lymph nodes in the left axilla, with a non-CR, non-PD evaluation. Chemotherapy with Pemetrexed + Carboplatin +

Event Overlapping

lymph nodes were observed in the mediastinum or at the hilum of both lungs. Bronchoscopy revealed extrinsic compression stenosis in the dorsal segment of the lower lobe of the right lung. Biopsy pathology indicated adenocarcinoma with an EGFR exon 19 mutation. The patient was treated with oral targeted therapy using Icotinib for

Entity Confusion

area). A PET/CT on January 28, 2023, showed postoperative and post-treatment changes in the left lung cancer compared to the PET/CT on November 22, 2021: 1) No high metabolism at the bronchial stump. New multiple patchy,

HOW TO

ACCURATELY identify and correlate event elements





EXHAUSTIVELY extract multiple medical events




► Large Language Models provide a new solution for Information Extraction

- Powerful ability of semantic understanding: new paradigm for IE
- Generative model: hallucination; need for optimization




- Post-hoc correction: effective improvement






Optimizing LLMs for MEE through Fine-tuning and Post-hoc Verification





Optimizing LLMs for MEE through Fine-tuning and Post-hoc Verification



Please complete the task of extracting medical event information from the provided clinical note:

The given clinical note includes clinical events belonging to the following four types:

#Imaging, Genetic Testing, Operation, Medication#.

Please return the extracted event time, event type, event project name, and conclusion for the medical event belonging to **#Imaging, Genetic Testing, Operation, Medication#** in JSON format:

```
{"time": "", "event_type": "", "project": "", "conclusion": ""};
```

if any information item is empty, please fill it with NONE.

Do not create events or times on your own.

The clinical note to extract is as follows:


```
"""{text}"""
```

...

```
{  
    "time": "2014-04",  
    "event_type": "Imaging",  
    "project": " chest CT scan",  
    "conclusion": " a nodule in the anterior segment of the left upper lobe of the lung"  
},  
{  
    "time": "2014-05-19",  
    "event_type": "Operation",  
    "project": "left upper lobe wedge resection ",  
    "conclusion": " squamous cell carcinoma, Grade II-III, in the left upper lobe of the lung"  
},  
...
```



► Parameter-efficient fine-tuning (PEFT)



MAIN-Dataset: 505 clinical notes on **medical history** of 158 patients with lung cancer from **Hospital A**

→ PEFT: train, validation, test (100 : 15 : 390)

To simulate the real situation in the clinical domain:
labeled data is limited


- QLoRA
- Finetuning with limited samples
- Align the model with annotation

Statistics	MAIN-Dataset
Total number of clinical notes	505
The average number of events per note	4.21
Maximum number of events in one note	9
Total number of @Imaging	759
Total number of @Operation	340
Total number of @Gene Test	77
Total number of @Medication	952



► Post-hoc Verification

- Error analysis on 108 extracted medical events from 50 clinical notes.



- Temporal Discrepancies

Cross-check: Locating by other elements

- Logic Ambiguity

Cross-check: Sequence of Project & Conclusion

- Event Duplication

Self-check: Repetition of three elements

- The Omission of Events

Chain-LLM: Detection & re-extraction

Extracted Event :

```
{  
  "time": "2015-2",  
  "event_type": "Imaging",  
  "project": "Chest CT",  
  "conclusion": "Left lung lesion enlarged compared to the previous state"  
}
```



In January 2015, the patient presented with hemoptysis without obvious triggers. The chest CT showed the left lung lesion enlarged compared to the previous state, which was not diagnosed and treated. In February 2015, the patient was re-admitted due to increased hemoptysis.


Corrected Event:

```
{  
  "time": "2015-1",  
  "event_type": "Imaging",  
  "project": "Chest CT",  
  "conclusion": "Left lung lesion enlarged compared to the previous state"  
}
```



► Post-hoc Verification

- Error analysis on 108 extracted medical events from 50 clinical notes.



- Temporal Discrepancies

Cross-check: Locating by other elements

- Logic Ambiguity

Cross-check: Sequence of Project & Conclusion

- Event Duplication

Self-check: Repetition of three elements

- The Omission of Events

Chain-LLM: Detection & re-extraction

Extracted Event :

```
{  
  "time": "2013-12",  
  "event_type": "Imaging",  
  "project": "Chest CT",  
  "conclusion": "The condition was stable."  
}
```

In November 2012, the chest CT showed the condition was stable. In December 2013, the chest CT suggested the lesion enlarged.

The conclusion is located before the project name.


Corrected Event:

```
{  
  "time": "2013-12",  
  "event_type": "Imaging",  
  "project": "Chest CT",  
  "conclusion": "The lesion enlarged."  
}
```



► Post-hoc Verification

- Error analysis on 108 extracted medical events from 50 clinical notes.



- Temporal Discrepancies

Cross-check: Locating by other elements

- Logic Ambiguity

Cross-check: Sequence of Project & Conclusion

- Event Duplication

Self-check: Repetition of three elements

- The Omission of Events

Chain-LLM: Detection & re-extraction

Extracted Event 1:

```
{  
  "time": "2021-08-10",  
  "event_type": "Imaging",  
  "project": "Chest CT",  
  "conclusion": "Bilateral intrapulmonary exudative changes"  
}
```

Self-check: SAME

Extracted Event 2:

```
{  
  "time": "2021-08-10",  
  "event_type": "Imaging",  
  "project": "Chest CT",  
  "conclusion": "Ground glass shadow shows no reduction"  
}
```


Merged Event:

```
{  
  "time": "2021-08-10",  
  "event_type": "Imaging",  
  "project": "Chest CT",  
  "conclusion": "Bilateral intrapulmonary exudative changes. Ground glass shadow shows no reduction"  
}
```



► Post-hoc Verification

- Error analysis on 108 extracted medical events from 50 clinical notes.



- Temporal Discrepancies
Cross-check: **Locating by other elements**
- Logic Ambiguity
Cross-check: **Sequence of Project & Conclusion**
- Event Duplication
Self-check: **Repetition of three elements**
- The Omission of Events
Chain-LLM: **Detection & re-extraction**

Extracted Event:

```
{  
  "time": "2022-11-10",  
  "event_type": "Operation",  
  "project": "puncture biopsy",  
  "conclusion": "Lung adenocarcinoma, predominantly alveolar, with genetic testing suggesting the EGFR exon 21 L858R mutation"}
```

Detection

Yes

LLM re-extraction

Extracted Event 1:

```
{  
  "time": "2022-11-10",  
  "event_type": "Operation",  
  "project": "puncture biopsy",  
  "conclusion": "Lung adenocarcinoma, predominantly alveolar"}
```

Extracted Event 2:

```
{  
  "time": "2022-11-10",  
  "event_type": "Genetic Testing",  
  "project": "Genetic Testing",  
  "conclusion": "genetic testing suggesting the EGFR exon 21 L858R mutation"}
```



► Results

Models	MicroF1	Operation			Imaging			Gene Test			Medication		
		Precision	Recall	F1 score	Precision	Recall	F1 score	Precision	Recall	F1 score	Precision	Recall	F1 score
Rule	0.513	0.625	0.714	0.667	0.447	0.514	0.478	0.727	1.000	0.842	0.717	0.223	0.340
ReDEE	0.415	0.250	0.312	0.278	0.727	0.121	0.208	0.188	0.328	0.239	0.400	0.563	0.468
Only-LLM	0.764	0.833	0.917	0.873	0.898	0.567	0.695	0.333	0.474	0.391	0.838	0.754	0.794
5-shot-LLM	0.592	0.944	0.756	0.840	0.739	0.472	0.576	1.000	0.438	0.609	0.902	0.354	0.508
QLoRA-LLM	0.804	0.803	0.770	0.786	0.740	0.767	0.753	0.360	0.450	0.400	0.892	0.851	0.871
OptimalMEE	0.902	1.000	0.960	0.979	0.835	0.880	0.857	0.769	1.000	0.870	0.912	0.908	0.910
w/o Duplication	0.890	1.000	0.960	0.979	0.817	0.880	0.847	0.704	0.950	0.809	0.916	0.874	0.895
w/o Omission	0.859	1.000	0.960	0.979	0.759	0.773	0.766	0.682	0.750	0.714	0.916	0.874	0.895
w/o Time	0.844	0.916	0.878	0.897	0.757	0.767	0.762	0.615	0.800	0.696	0.909	0.874	0.891
w/o Logic	0.888	0.930	0.892	0.910	0.818	0.862	0.840	0.769	1.000	0.870	0.919	0.905	0.912
Generalization	0.809	1.000	0.778	0.875	0.902	0.873	0.887	1.000	0.700	0.824	0.846	0.647	0.733

→ Generalization-Dataset: 16 clinical notes on **discharge summary** of 16 patients with lung cancer from **Hospital B**

- **The large language model** shows greater efficiency.

- **The PEFT method** aligns the model with limited annotation.

- **The post-hoc verifications** trace back and refine the output.



Patient Data Mining & Applications —— Tumor Board



浙江大學
ZHEJIANG UNIVERSITY

□ Application: TumorBoard


- ▶ Basic
- Basic Info.
- Diagnosis
- Staging

The screenshot shows the TumorBoard application interface. On the left, a green box highlights the 'Basic Info.' section, which includes the patient's name (田某), age (51), birth date (1970-07-07), gender (男), and clinical stage (T2b, N2, M1a, Stage IVa). In the center, a timeline shows various treatments and genetic test results. A purple box highlights the 'CT' examination on 2017-05-21. A blue box highlights the 'Genetic results parsing' for EGFR mutations on 2018-03-10. A pink box highlights the 'Medication' section on 2019-05-14.

- ▶ Timeline Navigator
- 1/ Visible OptimalMEE
- 2/ Multi-duration view
- 3/ Quick expert consensus

▶ Medication

Three screenshots of the TumorBoard application interface are shown. The first screenshot shows the 'CT' examination results with a timeline of findings from 2017-05-21 to 2019-05-14. The second screenshot shows the 'Genetic results parsing' for EGFR mutations with a table of results. The third screenshot shows the 'Medication' section with a table of treatments and a map showing locations.





□ Discussion & Conclusion

- Compared with traditional methods, the LLM-based Optimal MEE shows **low reliance on labor annotation**.
- The proposed four-step post-hoc verification could effectively improve the **accuracy** of the extracted events.
- The Optimal MEE provides **a solution** to information extraction in the clinical domain and lays the groundwork for further applications.

LIMITATIONS:

- **More generalizability evaluations** on wider datasets are needed
- High cost on **computational recourse**: GPU-based

IN THE FUTURE:

- Expansion of **data sources & broader needs**:
interaction with multi-dimension data and multiple clinical notes

Thank you!